H

Hospital Costa del Sol | Internal Medicine

Research site
(Unclaimed)
Location
A-7, Km 187, Marbella, Málaga, Spain

Site insights

Top conditions

Top treatments

Lenalidomide
Pomalidomide
Dexamethasone
Ibrutinib
Trastuzumab
Cobicistat
Emtricitabine
Tipifarnib
Efavirenz
Elvitegravir

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 88 total trials

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

The purpose of this study is to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length...

Active, not recruiting
Follicular Lymphoma
Drug: Rituximab - CHOP
Drug: Lenalidomide

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide
Recently updated

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymp...

Active, not recruiting
Peripheral T-cell Lymphoma
Drug: doxorubicin
Drug: prednisone

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling
RSV Infection
Drug: EDP-938
Drug: Placebo

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the...

Enrolling
B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Odronextamab

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Pomalidomide
Drug: mezigdomide

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab
Recently updated

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will stu...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Rituximab
Drug: Lenalidomide

The purpose of the phase Ib of the study is to identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM and to...

Active, not recruiting
Hodgkin Lymphoma
Drug: BrentuximabVedotin (BV)

The aim of the present study is to evaluate the effect of consumption during pregnancy and the lactation period of the probiotic L. fermentum CECT571...

Enrolling
Infant Health
Women's Health
Dietary Supplement: Maltodextrin
Dietary Supplement: Lactobacillus fermentum CECT5716

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are...

Enrolling
Pulmonary Arterial Hypertension
Drug: Placebo
Drug: Seralutinib

This phase III study, open-label, randomized study investigating lenalidomide and dexamethasone with and without biaxin in subjects with newly diagno...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Clarithromycin

Phase II study with a two-stage design to evaluate efficacy and safety of ibrutinib in combination with rituximab (I+R) in untreated patients with in...

Active, not recruiting
Mantle Cell Lymphoma
Drug: IBRUTINIB
Drug: Rituximab

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-H...

Active, not recruiting
HNSCC
HRAS Gene Mutation
Drug: Tipifarnib
Device: HRAS Detection Assay

The participants of this study would have relapsed/refractory follicular lymphoma.Follicular lymphoma is a type of blood cancer. It is referred to as...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Follicular Lymphoma
Combination Product: Rituximab
Drug: Placebo oral tablet

Trial sponsors

Celgene logo
Gilead Sciences logo
C
G
F
G
H
S
G
Loxo Oncology logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems